Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31582355

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2019 Nov
First author
Kato K

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Nov;20(11):1468-1469. doi: 10.1016/S1470-2045(19)30621-7.
    note
    Source null
    related pmid
    31582356
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2019 Dec;16(12):723. doi: 10.1038/s41571-019-0289-y.
    note
    Source null
    related pmid
    31616069
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2019 Nov;20(11):e613. doi: 10.1016/S1470-2045(19)30646-1.
    note
    Source null
    related pmid
    31674317
    relationship
    Erratum in

Authors and identifiers

  1. name
    Kato K
    type
    Author
  2. name
    Cho BC
    type
    Author
  3. name
    Takahashi M
    type
    Author
  4. name
    Okada M
    type
    Author
  5. name
    Lin CY
    type
    Author
  6. name
    Chin K
    type
    Author
  7. name
    Kadowaki S
    type
    Author
  8. name
    Ahn MJ
    type
    Author
  9. name
    Hamamoto Y
    type
    Author
  10. name
    Doki Y
    type
    Author
  11. name
    Yen CC
    type
    Author
  12. name
    Kubota Y
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Kato K
    type
    Author
  2. name
    Cho BC
    type
    Author
  3. name
    Takahashi M
    type
    Author
  4. name
    Okada M
    type
    Author
  5. name
    Lin CY
    type
    Author
  6. name
    Chin K
    type
    Author
  7. name
    Kadowaki S
    type
    Author
  8. name
    Ahn MJ
    type
    Author
  9. name
    Hamamoto Y
    type
    Author
  10. name
    Doki Y
    type
    Author
  11. name
    Yen CC
    type
    Author
  12. name
    Kubota Y
    type
    Author
bibliography ids
  1. nci-bib-600fcd8358ffc3c82fb8faab
book metadata
content sha256
6b5176108855ce610dee7d8cd92f3c4af2fefa7ccddc2b37b407b456ecb877cd
document type
citation
dois
  1. 10.1016/S1470-2045(19)30626-6
electronic publication date
display
2019 Sep 30
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31582355
immutable id
pubmed:31582355@6b5176108855ce610dee7d8cd92f3c4af2fefa7ccddc2b37b407b456ecb877cd
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1506-1517
volume
20
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Nov;20(11):1468-1469. doi: 10.1016/S1470-2045(19)30621-7.
    note
    Source null
    related pmid
    31582356
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2019 Dec;16(12):723. doi: 10.1038/s41571-019-0289-y.
    note
    Source null
    related pmid
    31616069
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2019 Nov;20(11):e613. doi: 10.1016/S1470-2045(19)30646-1.
    note
    Source null
    related pmid
    31674317
    relationship
    Erratum in
outcomes validated
false
pmid
31582355
provenance
batch id
23ffe1e2a9e160b6dca0
provider
NCBI PubMed ESummary
record sha256
0d8aa6e94c6ae80fc17bc6256bf5d75d61d0a4141dca71cff9207d99f1bed14e
response sha256
d5cbfde8f87ba85b214c53aaf0e8fa33d70fec48dd4fde7745538180cd7e1841
retrieved at
2026-09-09T23:47:44.690737+00:00
publication date
display
2019 Nov
precision
month
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31582355/
title
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice